AMIX (Autonomix Medical) 3-Year EPS without NRI Growth Rate: -7.20% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $2.76
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical 3-Year EPS without NRI Growth Rate?

Autonomix Medical AMIX +0.36% 15 3-Year EPS without NRI Growth Rate is -7.20% as of Mar. 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 660 Medical Devices & Instruments companies, Autonomix Medical ranks worse than 71.06% on this metric.

Autonomix Medical's EPS without NRI for the three months ended in Mar. 2026 was $-4.91.

During the past 3 years, the average EPS without NRI Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Autonomix Medical was -7.20% per year. The lowest was -7.20% per year. And the median was -7.20% per year.


Autonomix Medical  (NAS:AMIX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Autonomix Medical 3-Year EPS without NRI Growth Rate Related Terms


AMIX vs AEMD, NUMD, ESMC: 3-Year EPS without NRI Growth Rate Comparison

For the Medical Devices subindustry, Autonomix Medical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autonomix Medical 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Autonomix Medical's 3-Year EPS without NRI Growth Rate falls into.


AMIX
15GF Score
Autonomix Medical Inc AMIX
3-Year EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autonomix Medical 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

What does a 3-Year EPS without NRI Growth Rate of -7.20% mean?
Autonomix Medical (AMIX) has a 3-Year EPS without NRI Growth Rate of -7.20% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Autonomix Medical and its competitors. According to the industry distribution chart, Autonomix Medical ranks #469 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 71.1%.
Is Autonomix Medical's 3-Year EPS without NRI Growth Rate too high?
Autonomix Medical's current 3-Year EPS without NRI Growth Rate is -7.20%. Based on the distribution chart, Autonomix Medical ranks #469 out of 660 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's 3-Year EPS without NRI Growth Rate compare to AEMD and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #469 out of 660 companies for 3-Year EPS without NRI Growth Rate. This places Autonomix Medical in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.25, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current 3-Year EPS without NRI Growth Rate is -7.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current 3-Year EPS without NRI Growth Rate of -7.20%. The current 3-Year EPS without NRI Growth Rate is -7.20%. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current 3-Year EPS without NRI Growth Rate is -7.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.76
Price